Skip to main content
. 2019 Dec 12;12(1):1690959. doi: 10.1080/19420862.2019.1690959

Figure 6.

Figure 6.

CDC activity of anti-EGFR IgGs and their respective DuetMabs against EGFR tumor cells upon mCRP silencing. (a–c) CDC activity of QD6 (a), GA201 (b), and cetuximab (c) IgGs against siRNA-treated and untreated MDA-MB-468 at 10% (left), HCC827 at 10% (middle), and A431 cells at 5% (right) serum concentrations. (d–f) CDC activity of QD6/NMGC (d), GA201/NMGC (e), and cetuximab/NMGC (f) DuetMabs against siRNA-treated and untreated MDA-MB-468 at 10% (left), HCC827 at 10% (middle), and A431 cells at 5% (right) serum concentrations. NMGC was used as an isotype control. Each point represents the mean values of triplicate wells, and the standard error of the mean is represented by error bars.